Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

The recommendation also allows for people to "mix and match" vaccines for their booster dose.

CDC recommends booster shot for Moderna, Johnson & Johnson COVID-19 vaccines

An independent advisory board at the CDC says all adults who took Johnson & Johnson's coronavirus vaccine — and some high-risk adults who took Moderna's vaccine — should get an additional dose.

CDC Advisors Back Booster Shots For Moderna And J&J's Covid Vaccines

The committee leans into the FDA's authorization of a "mix and match" approach to COVID-19 boosters, meaning people wouldn't have to match their original shot.

CDC panel votes to recommend boosters for Moderna, Johnson & Johnson recipients

An influential CDC advisory committee on Thursday unanimously recommended boosters of Moderna's and Johnson & Johnson's Covid-19 vaccines.

CDC panel unanimously endorses Moderna and J&J Covid boosters, sending to director for final approval

NEW BRUNSWICK, N.J., Oct. 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2021 of $1.06 per share on the company's common stock.

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2021

TThe US health regulators have widened the country's COVID-19 vaccine campaign after the FDA-approved booster shots for Moderna Inc. (NASDAQ: MRNA) and Johnson & Johnson (NYSE: JNJ) vaccines. The FDA also indicated that people could receive a booster shot from either company irrespective of their vaccine before.

Here is why you need to mix and match Moderna and J&J COVID-19 booster shots

Bank of America

ConocoPhillips

Altria

Regions Financial

Worried about inflation that's turned out not to be so "transitory?" These seven safe stocks may be the place to be right now.

7 Safe Stocks to Own to Hedge Against Inflation

The Centers for Disease Control and Prevention on Thursday published data listing the most common side effects people reported after receiving Covid vaccine boosters.

CDC says these are the most common side effects people report after getting Moderna, J&J boosters

The FDA authorizes booster doses of COVID-19 vaccines of JNJ and MRNA. It also authorizes a heterologous boosting option which will allow administration of booster dose of any available vaccine irrespective of the primary vaccination regimen.

FDA Approves JNJ & MRNA's COVID-19 Boosters & Mixing of Doses

ARK Genomic Revolution Multi-Sector ETF

Novo Nordisk

Investing gets simple if you have to put all of your eggs in one basket.

If I Could Only Own 1 Healthcare Stock, This Is What It Would Be

Albemarle

Comcast

Enbridge

Home Depot

JPMorgan Chase & Co

Mondelez

Microsoft

ProShares S&P 500 Dividend Aristocrats ETF

Oracle

Procter & Gamble

STORE Capital

UnitedHealth Group

Visa

Vanguard Dividend Appreciation ETF

Walmart

Most dividend investors will not be able to retire on their own terms. This is because of a major flaw in the "dividend growth investing" philosophy.

Very Bad News For Dividend Investors (And How To Fix It)

The U.S. Food and Drug Administration on Wednesday approved booster shots of Moderna Inc.'s (NASDAQ: MRNA) and Jonson & Johnson's (NYSE: JNJ) COVID-19 vaccines as well as authorized “mixing and matching” of the booster doses. What Happened: The FDA said it has approved the booster shots of Moderna's COVID-19 vaccine for recipients aged 65 and older as well as some other vulnerable groups.

FDA Approves Moderna, Johnson & Johnson Booster And 'Mix And Match' COVID-19 Shots

NEW BRUNSWICK, N.J., Oct. 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine.

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA

The administration also said it'll allow eligible people to "mix and match" different COVID-19 shots when they get their booster.

FDA authorizes Moderna, Johnson & Johnson booster shots for many Americans

All three Covid-19 vaccines now have booster shots authorized — but eligibility for extra doses depends on the specific vaccine.

FDA Approves Moderna And J&J Covid Booster Shots, Signs Off On Mix-And-Match Approach — Here's Who Is Eligible

The FDA has authorized booster shots for Johnson & Johnson and Moderna's COVID-19 vaccines.

The FDA just authorized booster shots of Moderna's and Johnson & Johnson's COVID-19 vaccines and is letting users mix and match shots

WASHINGTON — U.S. regulators on Wednesday signed off on extending COVID-19 boosters to Americans who got the Moderna or Johnson & Johnson vaccine and said anyone eligible for an extra dose can get a brand different from the one they received initially.

FDA authorizes use of Moderna, Johnson & Johnson vaccine boosters

The Food and Drug Administration on Wednesday authorized Covid vaccine booster shots made by Johnson & Johnson and Moderna, another critical step in distributing the extra doses in the U.S.

FDA clears Johnson & Johnson and Moderna booster shots for millions of people

The 15 million people in the U.S. who got Johnson & Johnson's COVID-19 vaccine may soon have the option to get a second shot of their choosing.

People who got J&J's COVID-19 shot will soon be able to get a booster. Which one should they get?

Johnson & Johnson (JNJ) continued its long streak of earnings beat but lagged the revenue estimates. The company lifted its full-year guidance.

JNJ Posts Mixed Q3 Bag, Ups View: ETFs in Focus

There's more to the story than the healthcare giant's revenue and earnings numbers.

3 Things You Might Have Missed in Johnson & Johnson's Q3 Results

On Tuesday, Johnson & Johnson (NYSE:JNJ) shares gained 2.4% after announcing its most recent quarterly results. The company reported its fiscal third-quarter earnings per share before markets opened, beating analyst estimates.

Should you buy or sell JNJ shares after delivering mixed Q3 results?

The healthcare giant recorded healthy growth in all three of its business segments and raised its guidance.

Why Johnson & Johnson Shares Trounced the Market Today

AbbVie

Abbott Labs

Applied Materials

D.R. Horton

Gaming and Leisure Properties

Intel

Lowe's

Mastercard

Verizon

Xilinx

Kiplinger Investing publishes opportune source lists for investors online. Two recent billionaires stock-lists by Dan Burrows were published on 6/1/21 and 9/9/21.

News for Johnson & Johnson Stock (JNJ)